

# Infographic: Wales



NLCA

National Lung Cancer Audit

Summary of results for patients diagnosed in Wales 2024

Key improving from 2023 worsening from 2023 unchanged from 2023

## Diagnosis & staging

**2,135** people were diagnosed with lung cancer in 2024  
2,334 in 2023 & 2,211 in 2022

51% female  
 49% male

**73 years** median age at diagnosis

- 35%** of patients were diagnosed at **stage 1-2**  
34% in 2023 & 30% in 2022
- 44%** of patients presented with **stage 4 lung cancer**  
45% in 2023 & 47% in 2022
- 26%** of patients were diagnosed **after emergency admission**  
27% in 2023 & 29% in 2022

**Waiting times in Non-small Cell Lung Cancer (NSCLC)**

- 91 days** Median time from referral to **surgery** in NSCLC stage 1-2  
97 days in 2023
- 76 days** Median time from referral to **SACT** in NSCLC stage 3B-4  
78 days in 2023

## Treatment allocation

**Treatment with curative intent for Non-small Cell Lung Cancer (NSCLC)**

**78%** of patients with NSCLC (stage 1-2, Performance Status (PS) 0-2) received treatment with curative intent\*

\*surgery or radical radiotherapy

**≥80%** Audit standard  
77% in 2023  
76% in 2022

**62%** of patients with NSCLC (stage 3A, PS 0-2) received treatment with curative intent\*\*

\*\*surgery, radical radiotherapy or multimodal treatment

**N/A**

67% in 2023  
61% in 2022

**Surgery for Non-small Cell Lung Cancer (NSCLC)**

**17%** of patients with NSCLC had surgical treatment for their cancer

**≥17%** Audit standard  
18% in 2023  
14% in 2022

Absolute number of surgeries in 2024: 1,910

**Systemic Anti-Cancer Therapy (SACT) for Non-small Cell Lung Cancer (NSCLC)**

**62%** of patients with NSCLC (stage 3B-4, PS 0-1) received SACT

**≥70%** Audit standard  
55% in 2023  
60% in 2022

**Systemic Anti-Cancer Therapy (SACT) for Small Cell Lung Cancer (SCLC)**

**60%** of patients with SCLC received treatment with SACT

**≥70%** Audit standard  
65% in 2023  
71% in 2022

Median time from 'decision to treat' to start SACT: 16 days

**Survival outcomes**

2,135 patients were diagnosed between 1 January and 31 December 2024. For these patients:

**Median survival**

**350 days** 301 days in 2023  
262 days in 2022

**One year survival**

**49%** 46% in 2023  
43% in 2022

## Data quality

**Completeness of key routine data items**

Stage	Performance status	Basis of diagnosis	Morphology	Lung Clinical Nurse Specialist at diagnosis	Smoking status
<b>97%</b>	<b>98%</b>	<b>99%</b>	<b>100%</b>	<b>98%</b>	<b>72%</b>
<small>Audit standard</small>	<small>Audit standard</small>	<small>Audit standard</small>	<small>Audit standard</small>	<small>Audit standard</small>	<small>Audit standard</small>